Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New four-drug cocktail targets tough liver cancers with promising early trial

NCT ID NCT07350070

Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of four treatments for people with liver cancer that cannot be removed by surgery and who also have high blood pressure in the liver (portal hypertension). The goal is to see if adding a blood-pressure drug (carvedilol) to standard cancer therapies (TACE, immunotherapy, and a targeted drug) can improve tumor shrinkage and safety. About 78 adults aged 18-75 with newly diagnosed liver cancer will take part. The approach aims to control the disease while protecting the liver.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 78 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-75 years. * At least one radiologically measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (tumor lesion long axis ≥10 mm on CT scan). * Newly diagnosed hepatocellular carcinoma without any prior treatment for HCC. * Child-Pugh liver function score ≤ 7. * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1. * Absence of severe organic diseases affecting major organs (e.g., heart, lung, brain). * Compensated cirrhosis with clinically significant portal hypertension (meeting any one of the following criteria): 1. Imaging evidence (ultrasound, CT, or MRI) of portosystemic collateral circulation. 2. Endoscopic evidence of esophageal or gastric varices. 3. Liver stiffness measurement (LSM) \>25 kPa; or LSM 20-25 kPa with platelet count \<150×10⁹/L; or LSM 15-20 kPa with platelet count \<110×10⁹/L. Exclusion Criteria: * Decompensated cirrhosis. * Concurrent other malignancies or recurrent HCC. * Any active, known, or suspected autoimmune disease. * History of allergy to any component of PD-1 inhibitors, lenvatinib, or carvedilol. * Severe concurrent medical conditions, including asthma, significant cardiac conduction block, and sinus bradycardia. * Known human immunodeficiency virus (HIV) infection; or active hepatitis (e.g., hepatitis B/C virus infection). * Presence of tumor thrombus in the inferior vena cava, hepatic vein, or main portal vein.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver hepatocellular carcinoma portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC Liver cirrhosis Portal hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Hepatobiliary and Pancreatic Oncology

    Fuzhou, Fujian, China

  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430000, China

  • Hubei Province Tahe Hospital

    Taihe, Hubei, China

  • Organ Transplant Department,Qilu Hospital, Cheeloo College of Medicine, Shandong University,

    Jinan, Shandong, 250012, China

  • Qingdao University Affiliated Hospital

    Qingdao, Shandong, China

  • Shandong First Medical University Affiliated Provincial Hospital

    Jinan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.